PRESS RELEASE

Nano4Imaging new innovative start-up at Chemelot

Geleen, February 3rd 2011

Nano4Imaging starts a laboratory and production facility at the Chemelot Campus in Geleen. The technology of Nano4Imaging has opened up a new field where medical devices and implants can be marked for visibility in both MRI and more common imaging procedures. Product launch is foreseen in 2012 with a guidewire that can be used for medical interventions such as stent placement in the heart.

Nano4Imaging BV is part of a German holding with the same name and has been started January this year, to produce and modify medical devices for use in Magnetic Resonance Imaging (MRI). This imaging is superior in detection and treatment of disease “We produce nano-based contrast agents and put them on devices”, says CEO Paul Borm, “instead of injecting them into the bloodstream of patients.” Our technology enables the use of MRI in interventional procedures, at the same time keeping the advantages of conventional imaging such as X-ray and ultrasound. It has a bright future since it allows to combine the advantages of different equipment already available in most hospitals. At the same time the patient and doctors are less exposed to radiation such as in X-ray. Some medical applications such as stem cell delivery cannot be done under X-ray navigation, and the Magna4 technology of Nano4Imaging is indispensible”

Regional fit
Nano4Imaging fits perfectly into a modern approach where new materials are being developed to enable new applications in cardiovascular and regenerative medicine. With its focus on MRI a close link is also present to Maastricht Health Campus developments, focusing on the same technique. Our collaborations with universities in Maastricht, Aachen and Eindhoven are decisive for our research & development. In addition, the presence of rapid prototyping, imaging facilities and cleanrooms are essential factors for our development.

Spin-off across borders
Nano4Imaging has obtained venture capital from regional investors in the south of the Netherlands, including LIOF, Technostartfonds Zuidoost Nederland BV and Limburg Ventures (LIOF and DSM). Also two German venture funds (S-UBG from Aachen and BioScience Ventures Group from Munich) are shareholders. “We have investors and shareholders across the Dutch-German borders, which underlines the international profile of our company and activities,” Borm says. The S-UBG has many investments in promising enlarged SMEs, while BioScience Ventures Group (BSVG) extends its portfolio with companies active in early biotechnological developments. For its growth Nano4Imaging is seeking further capital. By the end of this year we will employ 4-5 people, and by the end of 2012 up to 10 employees.

About Chemelot
In the field of material sciences and life sciences the chemical industrial site Chemelot, in Geleen in the South of the Netherlands, is an important business partner in Western Europe. Chemelot comprises the Industrial Park and the Campus. The location has an excellent infrastructure and perfect logistics via water, rail and road. Chemelot offers raw materials, utilities, facilities, operational (plant) support, and an innovative knowledge ecosystem. With these, Chemelot facilitates new investments in research activities as well as innovative start-up companies and chemical installations. Some of the firms on Chemelot rank high on the list in their business
worldwide. The firms on Chemelot profit from operational synergy. However, Chemelot is more than the sum of these parts. Chemelot is also a ‘chemical innovation community’ where people, companies, and educational institutions share knowledge and involve in a creative cooperation to realize innovations and accelerated business growth. To stimulate the further development of the Chemelot Campus the Province of Limburg, DSM Nederland BV. and the Maastricht University/Maastricht UMC+ entered into a collaboration in 2010.